(Credit: Whyte et al)
After a heart attack, scar tissue that builds up around damaged blood vessels can precipitate ventricular or valve failure. Preventing this with medication requires either inaccurate systemic treatment - where doses must be kept low and the whole body is affected - or targeted drug delivery to the heart via multiple invasive surgeries.
The Therapi implant features a gelatin-based polymer reservoir where drugs can be stored and released locally to the damaged tissue. Attached via a surgical procedure, the reservoir can be refilled via a port on or just below the patient’s skin. The implant’s flat bottom consists of a semi-permeable membrane that can be adjusted to allow more drugs or larger materials to pass directly into the heart tissue.
Published in the journal Nature Biomedical Engineering, the research was led by Harvard University and featured input from MIT, Ireland’s Royal College of Surgeons, Trinity College Dublin, Advanced Materials and BioEngineering Research (AMBER) Centre, and National University of Ireland Galway.
“From a pharmacological point-of-view, it’s a big problem that you’re injecting something that doesn’t stay at the damaged tissue long enough to make a difference,” said William Whyte, co-first author and PhD candidate at Trinity College Dublin and AMBER.
“The material we used to construct the reservoir was crucial. We needed it to act like a sponge so it could retain the therapy exactly where you need it. That is difficult to accomplish since the heart is constantly squeezing and moving.”
(Credit: Whyte et al)
According to the team, Therapi is ideal for administering stem cell treatments, with the reservoir acting as something of a cell factory. Rather than pass through the membrane into the heart, the cells stay within the reservoir where they produce paracrine factors that promote healing in the damaged heart tissue.
In testing on rats, the device was found to improve cardiac function following a heart attack, with hearts that received multiple doses of therapy showing better results than those that were treated to just a single dose or no treatment at all.
“After a heart attack we could use this device to deliver therapy to prevent a patient from getting heart failure,” explained Ellen Roche, co-first author of the study and assistant professor at MIT’s Department of Mechanical Engineering and Institute for Medical Engineering and Science. “If the patient already has some degree of heart failure, we can use the device to attenuate the progression.”
While the team has been focusing on how Therepi can mitigate the effects of heart disease, the device could also be used in other parts of the body to treat a wide range of health issues.
“The device is really a platform that can be tailored to different organ systems and different conditions,” said Claudia Varela, a PhD student in the Harvard-MIT Division of Health Sciences and Technology. “It’s just a great example of how intersectional research looking at both devices and biological therapies can help us come up with new ways to treat disease.”
Oxa launches autonomous Ford E-Transit for van and minibus modes
I'd like to know where these are operating in the UK. The report is notably light on this. I wonder why?